Browse the evidence

Women with type 2 diabetes face a significantly higher relative risk of cardiovascular disease and mortality compared to men, despite often being diagnosed at a lower body mass index and younger age.

If you are a woman with type 2 diabetes, your risk of heart disease and death is higher relative to a man with diabetes, even if your weight is lower. This risk is amplified by hormonal changes like menopause and pregnancy history. You need aggressive management of blood pressure, lipids, and glucose, potentially starting earlier than guidelines might suggest for men, because your body may have more advanced heart vessel damage at the time of diagnosis.

Insulin resistance (IR) is a central pathophysiological mechanism that drives the development and progression of multiple metabolic diseases, including type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), and certain cancers.

Insulin resistance is not just a blood sugar issue; it is a systemic driver of chronic disease. Addressing it through lifestyle changes (exercise, diet) or medications (like metformin or GLP-1 agonists) can potentially improve multiple health outcomes at once, including heart health, liver health, and diabetes management. Prioritizing insulin sensitivity is a high-leverage strategy for overall metabolic health.

Obesity, particularly central/visceral obesity, is a primary cause of insulin resistance through mechanisms involving increased free fatty acids, chronic inflammation, and adipokine dysregulation.

Losing even a modest amount of weight (e.g., 10% of body weight) can significantly improve insulin sensitivity, especially if the weight is visceral fat. Focus on reducing abdominal fat through caloric deficit and exercise, as this directly addresses the root cause of obesity-induced insulin resistance.

Chronic low-grade inflammation, driven by obesity and characterized by elevated pro-inflammatory cytokines (TNF-alpha, IL-6, CRP), directly interferes with insulin signaling pathways, contributing to insulin resistance.

Chronic low-grade inflammation, common in obesity, disrupts insulin signaling. Anti-inflammatory lifestyle strategies (e.g., Mediterranean diet, regular exercise, stress management) can help reduce this inflammation and improve insulin sensitivity.

Obesity is fundamentally a state of chronic low-grade systemic inflammation driven by adipose tissue dysfunction, where an expansion of visceral fat leads to a shift from anti-inflammatory M2 macrophages to pro-inflammatory M1 macrophages, resulting in elevated levels of cytokines like TNF-alpha, IL-6, and resistin.

Recognize that obesity involves a biological inflammatory state, not just excess calories. This understanding shifts the focus from simple willpower to managing inflammation through medical and lifestyle interventions. While the paper highlights the problem, it notes that caloric restriction and regular exercise are effective interventions to reduce this inflammation and metabolic dysfunction.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) by 14% and all-cause mortality by 12% in patients with type 2 diabetes.

If you have Type 2 Diabetes and are at high risk for heart disease, ask your doctor about GLP-1 receptor agonists (like liraglutide or semaglutide). These medications have been shown to significantly reduce the risk of heart attacks, strokes, and death, in addition to helping with blood sugar control and weight loss.

Metformin reduces all-cause mortality by 36% and heart attack incidence by 39% in overweight patients with newly diagnosed type 2 diabetes without established cardiovascular disease.

If you have recently been diagnosed with Type 2 Diabetes and are overweight, metformin is likely your first medication. It not only helps control blood sugar but has been shown to significantly reduce the risk of heart attacks and death.

Women with PCOS have an increased risk of impaired glucose tolerance and type 2 diabetes regardless of age and BMI, necessitating routine glycaemic assessment.

If you have PCOS, you need to get your blood sugar checked regularly, even if you are thin. The condition itself raises your risk for diabetes, independent of your weight. Do not skip these tests because you feel healthy or look fit.

Women with PCOS are at increased risk for cardiovascular disease and mortality, requiring lipid and blood pressure monitoring regardless of age or BMI.

You need to have your blood pressure and cholesterol checked regularly, even if you are young and feel fine. PCOS increases your risk of heart disease and stroke. This is a standard part of managing PCOS, not just for older women.

Insulin resistance (IR) acts as a primary driver of cardiovascular disease (CVD) by promoting atherosclerosis through mechanisms including endothelial dysfunction, chronic low-grade inflammation, and dyslipidemia, independent of diabetes status.

Prioritize metabolic health markers like waist circumference and fasting insulin over just weight or cholesterol. Regular exercise and dietary modifications are the primary tools to improve insulin sensitivity and reduce cardiovascular risk, even if you are not diabetic.

Insomnia disorder is an independent risk factor for the development of mental health disorders, including depression, anxiety, and suicide, suggesting that treating insomnia may have preventive value for these conditions.

Treat insomnia seriously not just for sleep quality, but as a critical step in preventing depression and anxiety. Addressing sleep problems early may reduce the risk of developing these mental health conditions.

GLP-1 receptor agonists (Liraglutide, Semaglutide, Dulaglutide) significantly reduce liver fat content and improve liver enzymes in patients with Type 2 Diabetes and NAFLD, with Semaglutide showing histological resolution of NASH in Phase II trials.

If you have Type 2 Diabetes and NAFLD, ask your doctor about GLP-1 receptor agonists like Semaglutide or Liraglutide. These injectable medications have been shown in clinical trials to reduce liver fat and improve liver inflammation, in addition to helping with weight and blood sugar control.

SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Ipragliflozin) improve liver fat content and liver enzymes in patients with Type 2 Diabetes and NAFLD, with some evidence of improving liver fibrosis.

If you have Type 2 Diabetes and NAFLD, SGLT2 inhibitors like Empagliflozin or Dapagliflozin may help reduce liver fat and improve liver enzymes. Discuss these options with your doctor, especially if you are already managing your blood sugar with other medications.

Extending the dose-escalation period or temporarily suspending dose increases when gastrointestinal adverse events occur improves tolerability and treatment persistence without compromising long-term efficacy.

If you feel sick after a dose increase, don't rush to the next one. Stay at the current dose for a few extra weeks or pause until you feel better. This helps your body adjust and keeps you on the medication longer.

Pharmacological management of persistent nausea with domperidone (preferred over metoclopramide) or other anti-emetics/prokinetics is an effective strategy for managing GLP-1 RA-induced nausea when dietary and titration strategies fail.

If diet changes aren't enough, ask your doctor about domperidone. It is often preferred over other anti-nausea drugs because it has fewer serious side effects. Use it as needed for nausea.

Regular physical activity improves cortisol and dehydroepiandrosterone (sulphate) levels in older adults, contributing to healthy ageing.

Engage in regular physical activity, such as moderate-intensity exercise, to help regulate stress hormones like cortisol and DHEA(S), which supports healthy ageing and reduces frailty risk in older adults.

Sarcopenic obesity drives cardiovascular disease and mortality through mechanisms of chronic low-grade inflammation, insulin resistance, and lipotoxicity, creating a vicious cycle with cardiovascular conditions.

Understanding that fat and muscle loss interact to cause inflammation and heart risk highlights why treating both is crucial. Managing inflammation and insulin sensitivity through lifestyle can break this cycle.

Ether-linked phosphatidylethanolamines (specifically PE-P and PE-O) are associated with lower insulin resistance (SSPG) and healthier metabolic profiles, contrasting with other lipid classes like Ceramides and TAGs which increase with IR.

Not all phosphatidylethanolamines are equal. Ether-linked forms (PE-P and PE-O) are associated with lower insulin resistance, while standard PEs and Ceramides are linked to higher resistance. This highlights the importance of lipid subclass specificity in metabolic health.

High-intensity physical activity, particularly when performed in the evening or close to bedtime, is associated with poor sleep quality and difficulty initiating sleep.

If you exercise in the evening, avoid high-intensity workouts within 3 hours of bedtime. Opt for moderate intensity or finish your session earlier in the evening. High-intensity or long-duration (>90 min) evening exercise is linked to poorer sleep quality.

Severe sedentary behavior increases the risk of sleep disturbance, and this association is significantly mediated by elevated blood-cell-based inflammatory biomarkers (WBC, NEU, NLR, SII).

If you sit for more than 480 minutes a day (severe sedentary behavior), your risk of sleep disturbance increases. This risk is partly driven by your body's inflammatory response (measurable by blood tests). To mitigate this, you must break up long periods of sitting with movement, as this reduces the inflammatory burden that disrupts sleep.

High circulating levels of the artificial sweetener erythritol are associated with a significantly increased risk of major adverse cardiovascular events (MACE), including heart attack and stroke, and directly enhance platelet reactivity and thrombosis potential.

If you consume erythritol (a common artificial sweetener in 'keto' products, sugar-free drinks, and baked goods), be aware that it can accumulate in your blood and make your platelets more likely to form clots. This risk is particularly relevant if you have existing heart disease, diabetes, or high blood pressure. While occasional use may not pose a significant risk for healthy individuals, those at higher cardiovascular risk should consider limiting erythritol intake and consulting their doctor, especially given that levels can remain elevated for days after consumption.

Visceral adiposity, rather than overall body mass index (BMI), is the critical driver of metabolic syndrome comorbidities, including insulin resistance and cardiovascular risk.

Do not rely on BMI alone to assess your health risk. Waist circumference is a better indicator of visceral fat, which drives metabolic syndrome. Even if you are lean, high abdominal fat increases your risk for diabetes and heart disease.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced incidence of dementia in patients with type 2 diabetes.

If you have Type 2 Diabetes, discuss GLP-1 receptor agonists (like liraglutide or semaglutide) with your doctor. This paper suggests these medications may lower your risk of developing dementia compared to other diabetes treatments. This is particularly relevant if you are at high cardiovascular risk.

In Chinese adults with type 2 diabetes, higher levels of abdominal obesity indices (waist circumference, visceral adiposity index, lipid accumulation product, and Chinese visceral adiposity index) are significantly associated with an increased risk of incident cardiovascular events, with CVAI demonstrating the strongest predictive performance.

For people with type 2 diabetes, monitoring waist circumference or using calculated indices like CVAI is more critical for predicting heart disease risk than BMI alone. Reducing abdominal fat deposition is a key intervention strategy, particularly for those who are not overweight by BMI standards but carry visceral fat.